Global Oral Antidiabetic Drugs Market to reach USD 58.7 billion by 2027

Global Oral Antidiabetic Drugs Market Size study, by Drug (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 Receptor Agonist, Sodium - glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides) and Regional Forecasts 2020-2027
Product Code:  HALDAT_98206668
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1.	Oral Antidiabetic Drugs Market, by Region, 2018-2027 (USD Billion)
1.2.2.	Oral Antidiabetic Drugs Market, by Drug, 2018-2027 (USD Billion)
1.3.	Key Trends
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Oral Antidiabetic Drugs Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Scope of the Study
2.2.2.	Industry Evolution
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Oral Antidiabetic Drugs Market Dynamics	
3.1.	Oral Antidiabetic Drugs Market Impact Analysis (2018-2027)
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Oral Antidiabetic Drugs Market Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Suppliers
4.1.2.	Bargaining Power of Buyers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2.	PEST Analysis
4.2.1.	Political 
4.2.2.	Economical
4.2.3.	Social 
4.2.4.	Technological 
4.3.	Investment Adoption Model
4.4.	Analyst Recommendation & Conclusion
Chapter 5.	Global Oral Antidiabetic Drugs Market, by Drug 
5.1.	Market Snapshot 
5.2.	Global Oral Antidiabetic Drugs Market by Drug, Performance - Potential Analysis
5.3.	Global Oral Antidiabetic Drugs Market Estimates & Forecasts by Drug 2017-2027 (USD Billion)
5.4.	Oral Antidiabetic Drugs Market, Sub Segment Analysis
5.4.1.	Biguanides
5.4.2.	Alpha-glucosidase inhibitors
5.4.3.	Dopamine -D2 Receptor Agonist
5.4.4.	Sodium - glucose Cotransport -2 (SGLT-2) inhibitor
5.4.5.	Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
5.4.6.	Sulfonylureas
5.4.7.	Meglitinides
Chapter 6.	Global Oral Antidiabetic Drugs Market, Regional Analysis
6.1.	Oral Antidiabetic Drugs Market, Regional Market Snapshot 
6.2.	North America Oral Antidiabetic Drugs Market 
6.2.1.	U.S. Oral Antidiabetic Drugs Market	Drug breakdown estimates & forecasts, 2017-2027 
6.2.2.	Canada Oral Antidiabetic Drugs Market
6.3.	Europe Oral Antidiabetic Drugs Market Snapshot
6.3.1.	U.K. Oral Antidiabetic Drugs Market 
6.3.2.	Germany Oral Antidiabetic Drugs Market
6.3.3.	France Oral Antidiabetic Drugs Market
6.3.4.	Spain Oral Antidiabetic Drugs Market
6.3.5.	Italy Oral Antidiabetic Drugs Market
6.3.6.	Rest of Europe Oral Antidiabetic Drugs Market
6.4.	Asia-Pacific Oral Antidiabetic Drugs Market Snapshot
6.4.1.	China Oral Antidiabetic Drugs Market 
6.4.2.	India Oral Antidiabetic Drugs Market 
6.4.3.	Japan Oral Antidiabetic Drugs Market
6.4.4.	Australia Oral Antidiabetic Drugs Market
6.4.5.	South Korea Oral Antidiabetic Drugs Market
6.4.6.	Rest of Asia Pacific Oral Antidiabetic Drugs Market
6.5.	Latin America Oral Antidiabetic Drugs Market Snapshot
6.5.1.	Brazil Oral Antidiabetic Drugs Market
6.5.2.	Mexico Oral Antidiabetic Drugs Market
6.6.	Rest of The World Oral Antidiabetic Drugs Market
Chapter 7.	Competitive Intelligence
7.1.	Top Market Strategies
7.2.	Company Profiles
7.2.1.	Takeda Pharmaceutical Company Ltd.	Key Information	Overview	Financial (Subject to Data Availability)	Product Summary	Recent Developments
7.2.2.	Pfizer Inc.
7.2.3.	Eli Lilly and Company
7.2.4.	Janssen Pharmaceutica
7.2.5.	Astellas Pharma
7.2.6.	Boehringer Ingelheim Group
7.2.7.	Merck & Co., Inc.,
7.2.8.	AstraZeneca plc
7.2.9.	Novartis International AG
7.2.10.	Sanofi S.A.
Chapter 8.	Research Process
8.1.	Research Process
8.1.1.	Data Mining
8.1.2.	Analysis
8.1.3.	Market Estimation
8.1.4.	Validation
8.1.5.	Publishing
8.2.	Research Attributes
8.3.	Research Assumption

Global Oral Antidiabetic Drugs Market is valued at approximately USD 26.8 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2020-2027. Oral anti-diabetic drugs can be defined as a medication consumed orally which are recommended to heal diabetes mellitus (type 2). It treats diabetes mellitus by reducing the level of blood sugar level. These drugs often known as oral antihyperglycemic agents or oral hypoglycemic agents. Oral anti-diabetic drugs are also recommended as monotherapy, however in acute cases, and can be provided in blend with insulin. Rising incidences of diabetes across the globe, increasing aging population, and rapidly growing research and development efforts by pharmaceutical manufacturers to promote the demand for oral drugs are the few other factors driving the market growth during the forecast period. According to the International Diabetic Federation (IDF), the prevalence of diabetes among adults (20-79 years) was about 463 million adults in 2019, and this estimation is likely to grow almost 700 million by the year 2045. Similarly, as per the IDF Diabetes Atlas in 2019, the number of diabetic patients in Europe is expected to reach around 68 million by 2045, with total health expenditure for diabetes almost USD 214 billion. This, in turn, is expected to accelerate the usage of Oral Antidiabetic Drugs all over the world. Amidst the COVID-19 outbreak around the world, the pharma industry is more concerned about the development of the COVID-19 vaccine, thus, R&D efforts for oral antidiabetic drugs is substantially decline. Though, the demand for oral anti-diabetic drugs is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at a significant rate in the forthcoming years. However, the high cost of oral antidiabetic drugs is one of the major factors impeding the growth of the market over the forecast period of 2020-2027.

The regional analysis of the global Oral Antidiabetic Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising prevalence of diabetes, coupled with the introduction of new anti-diabetic drugs with improve efficacy in the region. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as growing diabetic population, coupled with improving healthcare infrastructure would create lucrative growth prospects for the demand of Oral Antidiabetic Drugs in the region.

Major market player included in this report are:
Takeda Pharmaceutical Company Ltd.
Pfizer Inc.
Eli Lilly and Company
Janssen Pharmaceutica
Astellas Pharma
Boehringer Ingelheim Group
Merck & Co., Inc.,
AstraZeneca plc
Novartis International AG
Sanofi S.A.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug:
Alpha-glucosidase inhibitors
Dopamine -D2 Receptor Agonist
Sodium – glucose Cotransport -2 (SGLT-2) inhibitor
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors

By Region:
North America

Asia Pacific
South Korea
Latin America
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Oral Antidiabetic Drugs Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.